Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TTY Biopharm CoROCO:4105 +1.28%83 ROA % is 15.39% as of Mar. 2026, which is 24% above its 10-year median of 12.38. GuruFocus rates ROCO:4105 with a GF Score™ of 83/100 and a GF Value™ of NT$87.56 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 1,007 Drug Manufacturers companies, TTY Biopharm Co ranks better than 91.06% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. TTY Biopharm Co's annualizedNet Income for the quarter that ended in Mar. 2026 was NT$1,772 Mil.
TTY Biopharm Co's average Total Assets over the quarter that ended in Mar. 2026 was NT$11,512 Mil. Therefore, TTY Biopharm Co's annualized ROA % for the quarter that ended in Mar. 2026 was 15.39%.
The historical rank and industry rank for TTY Biopharm Co's ROA % or its related term are showing as below:
ROCO:4105'
s ROA % Range Over the Past 10 Years
Min: 8.92 Med: 12.38 Max: 15.75
Current: 14.33
During the past 13 years, TTY Biopharm Co's highest ROA % was 15.75%. The lowest was 8.92%. And the median was 12.38%.
ROCO:4105's ROA % is ranked better than 91.06% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 2.78
vs ROCO:4105: 14.33
TTY Biopharm Co (ROCO:4105) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
TTY Biopharm Co ROA % Related Terms
TTY Biopharm Co ROA % Historical Data
* Premium members only.
The historical data trend for TTY Biopharm Co's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, TTY Biopharm Co's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TTY Biopharm Co ROA % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, TTY Biopharm Co's ROA % distribution charts can be found below:
* The bar in red indicates where TTY Biopharm Co's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
TTY Biopharm Co (ROCO:4105) has a ROA % of 15.39% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on TTY Biopharm Co and its competitors. This is 24% above median its historical median of 12.38. Over the past decade, TTY Biopharm Co's ROA % has ranged from 8.92 to 15.75. According to the industry distribution chart, TTY Biopharm Co ranks #90 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 8.9%.
Is TTY Biopharm Co's ROA % too high?
TTY Biopharm Co's current ROA % of 15.39% is 24% above median its 10-year median of 12.38. Over the past 10 years, this metric has ranged from a low of 8.92 to a high of 15.75. The Drug Manufacturers industry median ROA % is 2.78. TTY Biopharm Co's value of 15.39% is 453.6% above this industry median. Based on the distribution chart, TTY Biopharm Co ranks #90 out of 1007 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, TTY Biopharm Co has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TTY Biopharm Co's ROA % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, TTY Biopharm Co ranks #90 out of 1007 companies for ROA %. This places TTY Biopharm Co in the top 9% of its industry — outperforming the majority of peers. The industry median ROA % is 2.78. TTY Biopharm Co's value of 15.39% is 453.6% above this benchmark. Historically, TTY Biopharm Co's own ROA % has ranged from 8.92 to 15.75 over the past decade. While the company's 10-year median is 12.38 vs. the industry median of 2.78, TTY Biopharm Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.78, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TTY Biopharm Co's current ROA % of 15.39% is 453.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on TTY Biopharm Co and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TTY Biopharm Co's current ROA % is 15.39%, which is 24% above median its own 10-year median of 12.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TTY Biopharm Co stock overvalued right now?
Based on GuruFocus' analysis, TTY Biopharm Co (ROCO:4105) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$87.56, compared to a current price of NT$79.10 — trading 9.7% below its estimated fair value. The current ROA % is 15.39%, which is 24% above median its 10-year median of 12.38 and 453.6% above the Drug Manufacturers industry median of 2.78. TTY Biopharm Co's overall GF Score™ is 83/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For TTY Biopharm Co (ROCO:4105), the current ROA % is 15.39% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TTY Biopharm Co (ROCO:4105) Overvalued in 2026?
Based on GuruFocus' analysis, TTY Biopharm Co stock appears to be undervalued.
The current stock price of NT$79.10 is trading 9.7% below its estimated GF Value™ of NT$87.56.
GuruFocus considers TTY Biopharm Co to be Modestly Undervalued.
Key valuation signals for ROCO:4105:
ROA %: 15.39% (24% above median its 10-year median of 12.38)
GF Value™: NT$87.56 vs. price of NT$79.10 (9.7% below fair value)
Industry Position: 453.6% above the Drug Manufacturers median (#90 of 1007)
No single metric tells the full story. See the ROCO:4105 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TTY Biopharm Co Ltd is engaged in the manufacturing and marketing of pharmaceuticals and chemical drugs. The company's operating segments includes Oncology Business unit, Health Care Business unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business unit segment. It generates maximum revenue from the Oncology segment. Geographically, it derives a majority of revenue from Taiwan and also has a presence in America. Some of its products include Algitab, Alginos, Sulfin, Metacin, Cepiro, Brosym, Colimycin, Cubicin, and others.
83GF Score
Get the complete analysis for ROCO:4105
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4105 has been successfully added to your 
